Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 2
2000 1
2002 1
2016 2
2017 1
2018 1
2019 3
2020 3
2021 3
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Histologic transformation of epidermal growth factor receptor-mutated lung cancer.
Fujimoto D, Akamatsu H, Morimoto T, Wakuda K, Sato Y, Kawa Y, Yokoyama T, Tamiya M, Hiraoka R, Shingu N, Ikeda H, Tamiya A, Kanazu M, Miyauchi E, Miura S, Yanai M, Yomota M, Morinaga R, Yokoi T, Hata A, Suzuki H, Matsumoto H, Sakata S, Furuya N, Harutani Y, Nakachi I, Otsuki A, Uematsu S, Hara S, Yokoo K, Sugimoto T, Yamamoto N. Fujimoto D, et al. Among authors: shingu n. Eur J Cancer. 2022 May;166:41-50. doi: 10.1016/j.ejca.2022.02.006. Epub 2022 Mar 9. Eur J Cancer. 2022. PMID: 35278824
Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003).
Ishii H, Azuma K, Shimose T, Yoshioka H, Kurata T, Shingu N, Okamoto M, Kawashima Y, Okamoto I. Ishii H, et al. Among authors: shingu n. Thorac Cancer. 2023 Jan;14(1):105-107. doi: 10.1111/1759-7714.14727. Epub 2022 Nov 15. Thorac Cancer. 2023. PMID: 36380738 Free PMC article.
Clinical phenotypes from fatal cases of acute respiratory distress syndrome caused by pneumonia.
Ichikado K, Kawamura K, Johkoh T, Fujimoto K, Shintani A, Hashimoto S, Eguchi Y, Yasuda Y, Anan K, Shingu N, Sakata Y, Hisanaga J, Nitawaki T, Iio M, Sekido Y, Nishiyama K, Nakamura K, Suga M, Ichiyasu H, Sakagami T. Ichikado K, et al. Among authors: shingu n. Sci Rep. 2021 Oct 8;11(1):20051. doi: 10.1038/s41598-021-99540-1. Sci Rep. 2021. PMID: 34625618 Free PMC article.
Clinical outcomes and predictive value of programmed cell death-ligand 1 expression in response to anti-programmed cell death 1/ligand 1 antibodies in non-small cell lung cancer patients with performance status 2 or greater.
Jodai T, Saruwatari K, Ikeda T, Moriyama E, Kashiwabara K, Shingu N, Iyonaga K, Inaba M, Ajishi Y, Honda C, Hirosako S, Maruyama H, Kakiuchi Y, Eida H, Tomita Y, Saeki S, Ichiyasu H, Sakagami T. Jodai T, et al. Among authors: shingu n. Int J Clin Oncol. 2021 Jan;26(1):78-86. doi: 10.1007/s10147-020-01789-5. Epub 2020 Sep 23. Int J Clin Oncol. 2021. PMID: 32965577
Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases.
Saruwatari K, Ikeda T, Saeki S, Shingu N, Imamura K, Komatu T, Ushijima S, Maruyama H, Kashiwabara K, Tomita Y, Ichiyasu H, Fujii K, Sakagami T. Saruwatari K, et al. Among authors: shingu n. Anticancer Res. 2019 Feb;39(2):923-931. doi: 10.21873/anticanres.13195. Anticancer Res. 2019. PMID: 30711977
The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment.
Sakata Y, Kawamura K, Ichikado K, Shingu N, Yasuda Y, Eguchi Y, Anan K, Hisanaga J, Nitawaki T, Iio M, Sekido Y, Nakano A, Sakagami T. Sakata Y, et al. Among authors: shingu n. Lung Cancer. 2019 Apr;130:159-161. doi: 10.1016/j.lungcan.2019.02.011. Epub 2019 Feb 14. Lung Cancer. 2019. PMID: 30885338
Comparisons between tumor burden and other prognostic factors that influence survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
Sakata Y, Kawamura K, Ichikado K, Shingu N, Yasuda Y, Eguchi Y, Hisanaga J, Nitawaki T, Iio M, Sekido Y, Nakano A, Sakagami T. Sakata Y, et al. Among authors: shingu n. Thorac Cancer. 2019 Dec;10(12):2259-2266. doi: 10.1111/1759-7714.13214. Epub 2019 Nov 3. Thorac Cancer. 2019. PMID: 31679185 Free PMC article.
17 results